Patent: 10,385,131
✉ Email this page to a colleague
Summary for Patent: 10,385,131
Title: | Combination therapies of HDAC inhibitors and PD-L1 inhibitors |
Abstract: | Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors. |
Inventor(s): | Bissonnette; Reid P. (Carlsbad, CA), Rolland; Alain (San Diego, CA), Gillings; Mireille (Winchester CDP, NV) |
Assignee: | HUYA Bioscience International, LLC (San Diego, CA) |
Application Number: | 15/592,929 |
Patent Claims: | see list of patent claims |
Details for Patent 10,385,131
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2036-05-11 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 03/08/2019 | ⤷ Try a Trial | 2036-05-11 |
Emd Serono, Inc. | BAVENCIO | avelumab | Injection | 761049 | 03/23/2017 | ⤷ Try a Trial | 2036-05-11 |
Astrazeneca Uk Ltd | IMFINZI | durvalumab | Injection | 761069 | 05/01/2017 | ⤷ Try a Trial | 2036-05-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |